VCD 088
Alternative Names: VCD-088Latest Information Update: 28 Jul 2022
Price :
$50 *
At a glance
- Originator Vyome Biosciences
- Developer Brigham and Women's Hospital; Vyome Therapeutics
- Class Antibacterials; Fluoroquinolones
- Mechanism of Action Bacterial adhesin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone and joint infections
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Bone-and-joint-infections in India
- 07 Jun 2018 Preclinical trials in Bone and joint infections in India (unspecified route) before June 2018
- 07 Jun 2018 Antimicrobial data from the preclinical studies in Bone infections presented at the American Society for Microbiology's Microbe 2018 (ASMM-2018)